-
Posted: September 3rd, 2008, 6:00am EDT
Pfizer announced that in patients with established heart disease, LipitorĀ® (atorvastatin calcium) 80 mg not only significantly reduced the relative risk of suffering a first cardiovascular event by 19 percent compared to Lipitor 10 mg but also provided a sustained reduction in the risk of a subsequent second, third, fourth, and fifth cardiovascular event, according to a subanalysis of the five-year Treating to New Targets (TNT) study.
-
Posted: September 3rd, 2008, 5:00am EDT
The link between cholesterol-lowering drug ezetimibe (marketed as Vytorin) and cancer is still not clear, wrote the editors of the leading medical journal New England Journal of Medicine (NEJM). More time is needed to assess the drug, they said, and in the meantime patients and doctors will have to live with the uncertainty.
-
Posted: September 3rd, 2008, 4:00am EDT
Cardiologists in Europe agree that reducing LDLcholesterol (LDL-C or "bad" cholesterol) is the most important consideration when treating dyslipidaemia (abnormal blood lipids). A majority of cardiologists also agree that in addition to lowering LDL-C, raising HDL-cholesterol (HDL-C or "good" cholesterol) and reducing triglycerides are important factors in choosing dyslipidaemia treatment.